Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate

Journal of Urology

Volumn 166, Issue 6, 2001, Pages 2484-2490

  Ückert, Stefan ^a   Küthe, Andrea ^a   Jonas, Udo ^a   Stief, Christian G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Phosphodiesterase inhibitors; Phosphoric diester hydrolases; Prostate; Prostatic hyperplasia

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; FORSKOLIN; NITROPRUSSIDE SODIUM; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SILDENAFIL; VINPOCETINE; ZAPRINAST;

ADRENERGIC ACTIVITY; ARTICLE; DRUG EFFECT; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROLYSIS; KIDNEY FAILURE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE RELAXATION; URETHRA OBSTRUCTION; URINE RETENTION;

EID: 0035174618     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65621-2     Document Type: Article

References (34)

1. Epidemiology and natural history of benign prostatic hyperplasia
2. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia
3. A population-based study of health care-seeking behaviour for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men
4. Benign prostatic hyperplasia. Medical and minimally invasive treatment options
5. Azasteroids as inhibitors of rat prostatic 5-alpha reductase
6. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: A pilot study
7. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study
8. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck
9. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview
10. Medical management of BPH
11. Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes
12. Placebo-controlled, double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation
13. Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH
14. Wirksamkeit und Verträglichkeit von Mepartricin (Iperplasin) bei Benigner Prostatahyperplasie: Ergebnisse einer Anwendungsbeobachtung. Iperplasin Anwendungsbeobachtungsgruppe Österreich
15. Pharmacological characterization of the isolated canine prostate
16. LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions
17. Prostate growth factors and benign prostatic hyperplasia
18. Calcitonin gene-related peptide (CGRP) inhibits contractions of the prostatic stroma of the rat but not the guinea-pig
19. Smooth muscle contractility in prostatic hyperplasia: Role of cyclic adenosine monophosphate
20. Isoenzyme selective phosphodiesterase inhibitors: Potential clinical uses
21. The effect of the specific phosphodiesterase 4 inhibitor rolipram on the ureteral peristalsis in vitro and in vivo
22. Initial clinical experience with the selective phosphodiesterase (PDE) 1 isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder
23. Relaxation of human detrusor smooth muscle in vitro by modulation of cyclic nucleotide dependent pathways
24. DNA-sequencing with chain-terminating inhibitors
25. Multiple cyclic nucleotide phosphodiesterase activity from rat brain
26. Neuroendocrine peptides stimulate adenylyl cyclase in normal and malignant prostate cells
27. Regulation of smooth muscle contractile elements by second messengers
28. Advances in the pharmacological control of the bladder
29. Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and cyclic GMP-dependent mechanisms
30. Identification of 13 phosphodiesterase isoforms in human cavernous tissue
31. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isoenzymes in canine tracheal smooth muscle
32. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
33. Effects of nitric oxide on human and canine prostates